Miteshkumar Maurya
Research Subjects
Miteshkumar Maurya has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Renuka Munshi
Department of Clinical Pharmacology, Topiwala National Medical College and BYL Nair Charitable Hospital, Mumbai Central, Mumbai, Maharashtra, India
7 shared publications - Debdipta Bose
Department of Clinical Pharmacology, Seth GS Medical College & KEM Hospital, Parel-400 012, Mumbai, Maharashtra, India
3 shared publications - Mahanjit Konwar
Department of Clinical Pharmacology, Seth GS Medical College and KEM Hospital, Mumbai, Maharashtra, India
3 shared publications Renju Ravi
Seth Gordhandas Sunderdas Med Coll, Dept Clin Pharmacol, Mumbai, Maharashtra, India
2 shared publications- Renju Ravi
Department of Clinical Pharmacology, Faculty of Medicine, Jazan University, Jazan, Saudi Arabia
2 shared publications Renuka Munshi
2 shared publications
Latest Publications
- Open Access
- 15 October 2024
- Published by Forum for Medical Ethics Society in Indian Journal of Medical Ethics
- Vol. 9 (4) , 296-300
Reasons for retraction of clinical research articles in PubMed indexed medical journals from 2012 to 2022
Background: Misconduct in the publication of research articles is a serious concern for the scientific community. This study was conducted with the objective to assess various reasons for retraction of clinical research articles published in PubMed indexed journals from all over the world since 2012 to 2022. Methods: A search was performed on the PubMed database for retracted research articles using filters for “retracted publication”. A total of 314 eligible research articles were assessed for studying basic details. The study outcome measures were to evaluate the reasons for the retraction and authors’ and journal editors’ responses to retractions. Results: Of the original research articles retracted, 150/242 (61.98%) were clinical trial publications. Of the total 314 retracted research articles, the most retractions were in 2014 (47, 14.96%) and 2013 (40, 12.73%) while the fewest retractions were in 2012 (3, 0.95%) and 2022 (9, 2.86%). The most common reasons for retraction were data errors or data analysis errors (120/314, 38.21%) followed by plagiarism (37/314, 11.8%), duplicate publication (35/314, 11.1%), ethical concerns (23/314, 7.3%) and methodological flaws (22/314, 7%). These concerns were raised mainly by the editor or editor-in-chief (228/314, 72.61%), followed by authors (29/314, 9.23%). Out of 228 editorial concerns on publications, authors of only 91/228 (39.91%) agreed and 17/228 (7.45%) completely disagreed with the editorial decision. Conclusion: Authors need to be more careful about data analysis errors, fabricated or falsified data, and plagiarism while submitting their research papers. On the part of editors, detecting misconduct at the submission and peer review stages will help lower the retraction rate and avoid citation of such articles by other authors.
- 15 October 2024
- Published by Forum for Medical Ethics Society in Indian Journal of Medical Ethics
- Vol. 9 (4) , 296-300
Open AccessReasons for retraction of clinical research articles in PubMed indexed medical journals from 2012 to 2022
Background: Misconduct in the publication of research articles is a serious concern for the scientific community. This study was conducted with the objective to assess various reasons for retraction of clinical research articles published in PubMed indexed journals from all over the world since 2012 to 2022. Methods: A search was performed on the PubMed database for retracted research articles using filters for “retracted publication”. A total of 314 eligible research articles were assessed for studying basic details. The study outcome measures were to evaluate the reasons for the retraction and authors’ and journal editors’ responses to retractions. Results: Of the original research articles retracted, 150/242 (61.98%) were clinical trial publications. Of the total 314 retracted research articles, the most retractions were in 2014 (47, 14.96%) and 2013 (40, 12.73%) while the fewest retractions were in 2012 (3, 0.95%) and 2022 (9, 2.86%). The most common reasons for retraction were data errors or data analysis errors (120/314, 38.21%) followed by plagiarism (37/314, 11.8%), duplicate publication (35/314, 11.1%), ethical concerns (23/314, 7.3%) and methodological flaws (22/314, 7%). These concerns were raised mainly by the editor or editor-in-chief (228/314, 72.61%), followed by authors (29/314, 9.23%). Out of 228 editorial concerns on publications, authors of only 91/228 (39.91%) agreed and 17/228 (7.45%) completely disagreed with the editorial decision. Conclusion: Authors need to be more careful about data analysis errors, fabricated or falsified data, and plagiarism while submitting their research papers. On the part of editors, detecting misconduct at the submission and peer review stages will help lower the retraction rate and avoid citation of such articles by other authors.
- 1 May 2024
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 19 (2) , 286-290
A Case Report of Cefixime, Paracetamol, and Nimesulide Induced Toxic Epidermal Necrolysis in a Woman with Dengue Infection without any Other Associated Comorbidities
Background: Toxic Epidermal Necrolysis (TEN) is a rare, acute, and life-threatening mucocutaneous disease that occurs after the administration of certain drugs, resulting in extensive keratinocyte cell death, skin involvement at the dermal-epidermal junction, and extensive bullous skin eruptions and sloughing. Many published case reports have observed the presence of fever with a viral infection, drug, and/or genetic association as a possible trigger for TEN but associated with other comorbidities. Physicians still struggle to predict which individuals could be predisposed to TEN. The case report that we present had a history of multiple drug intake and fever due to dengue virus infection but was not associated with any other comorbidity. Case Presentation: We present an unusual case of a 32-year-old woman of Western Indian origin who had developed dengue infection and suffered toxic epidermal necrolysis following a five-day course of a third-generation cephalosporin antibiotic, cefixime and a three-day course of 2 analgesic drugs, paracetamol (acetaminophen), and nimesulide, with the adverse event occurring on the fifth day of the dengue infection. The offending drugs were stopped, and patient survived with supportive management and hydration. Conclusion: The presence of comorbidities may not always be the triggering factor for TEN, though it can affect patient outcomes. Rational drug use is always recommended for patient care. Further research is required to understand the pathomechanism behind the viral-drug-gene interaction.
- 1 May 2024
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 19 (2) , 286-290
A Case Report of Cefixime, Paracetamol, and Nimesulide Induced Toxic Epidermal Necrolysis in a Woman with Dengue Infection without any Other Associated Comorbidities
Background: Toxic Epidermal Necrolysis (TEN) is a rare, acute, and life-threatening mucocutaneous disease that occurs after the administration of certain drugs, resulting in extensive keratinocyte cell death, skin involvement at the dermal-epidermal junction, and extensive bullous skin eruptions and sloughing. Many published case reports have observed the presence of fever with a viral infection, drug, and/or genetic association as a possible trigger for TEN but associated with other comorbidities. Physicians still struggle to predict which individuals could be predisposed to TEN. The case report that we present had a history of multiple drug intake and fever due to dengue virus infection but was not associated with any other comorbidity. Case Presentation: We present an unusual case of a 32-year-old woman of Western Indian origin who had developed dengue infection and suffered toxic epidermal necrolysis following a five-day course of a third-generation cephalosporin antibiotic, cefixime and a three-day course of 2 analgesic drugs, paracetamol (acetaminophen), and nimesulide, with the adverse event occurring on the fifth day of the dengue infection. The offending drugs were stopped, and patient survived with supportive management and hydration. Conclusion: The presence of comorbidities may not always be the triggering factor for TEN, though it can affect patient outcomes. Rational drug use is always recommended for patient care. Further research is required to understand the pathomechanism behind the viral-drug-gene interaction.
- Open Access
- 12 July 2023
- Published by IntechOpen
Perspective Chapter: Drug-Induced Severe Cutaneous Adverse Reactions, Diagnostics and Management
Severe cutaneous Adverse Reactions (SCAR) are rare drug hypersensitivity reactions but can be life-threatening if not appropriately and timely managed. Many research studies have shed light on its pathomechanism and triggers that have helped us better understand SCAR. The presence of viral fever and genetics such as HLA genotype with certain drugs have been associated with the occurrence of SCAR. However, the basis of interaction of these causative agents needs further evaluation to understand the predisposition to the reaction occurrence. The different spectrum of SCAR needs to be clinically diagnosed appropriately which includes Drug Reactions with Eosinophilia and Systemic Symptoms (DRESS), Steven Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN), Acute Generalized Exanthematous Pustulosis (AGEP), and generalized bullous fixed drug eruptions (GBFDE). However, due to the rare occurrence of this reaction, there is not sufficient evidence for the best treatment for patients suffering from SCAR. Our review provides detailed information about the disease type, manifestation, pathophysiology, diagnostics, and current treatment aspects of SCAR.
- 12 July 2023
- Published by IntechOpen
Open AccessPerspective Chapter: Drug-Induced Severe Cutaneous Adverse Reactions, Diagnostics and Management
Severe cutaneous Adverse Reactions (SCAR) are rare drug hypersensitivity reactions but can be life-threatening if not appropriately and timely managed. Many research studies have shed light on its pathomechanism and triggers that have helped us better understand SCAR. The presence of viral fever and genetics such as HLA genotype with certain drugs have been associated with the occurrence of SCAR. However, the basis of interaction of these causative agents needs further evaluation to understand the predisposition to the reaction occurrence. The different spectrum of SCAR needs to be clinically diagnosed appropriately which includes Drug Reactions with Eosinophilia and Systemic Symptoms (DRESS), Steven Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN), Acute Generalized Exanthematous Pustulosis (AGEP), and generalized bullous fixed drug eruptions (GBFDE). However, due to the rare occurrence of this reaction, there is not sufficient evidence for the best treatment for patients suffering from SCAR. Our review provides detailed information about the disease type, manifestation, pathophysiology, diagnostics, and current treatment aspects of SCAR.
- 15 March 2023
- Published by Springer Nature
- p. 113-131
A Comprehensive Review of the Impact of the Renin Angiotensin System in the Liver, Lung, Infectious Diseases and Cancers
- 15 March 2023
- Published by Springer Nature
- p. 113-131
A Comprehensive Review of the Impact of the Renin Angiotensin System in the Liver, Lung, Infectious Diseases and Cancers
- 1 February 2023
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 24 (2) , 151-156
Melanocortin Receptors: Emerging Targets for the Treatment of Pigmentation, Inflammation, Stress, Weight Disorders and Sexual Dysfunction
Melanocortins are tiny protein molecules formed by the post-translational cleavage of proopiomelanocortin. These are bioactive peptides that are responsible for human and lower animal pigmentation patterns, energy homeostasis, and sexual function modulation. These peptides regulate numerous physiological functions by being generated in the central nervous system and peripheral tissues. Melanocortins elicit their varied biological effects by binding to a separate family of G protein, two primary proteolytic enzymes, proconvertases 1 and 2, according to the recent research. These breakthroughs have opened up new avenues for research into the role of melanocortins, antagonists, and receptors in a number of physiological activities.
- 1 February 2023
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 24 (2) , 151-156
Melanocortin Receptors: Emerging Targets for the Treatment of Pigmentation, Inflammation, Stress, Weight Disorders and Sexual Dysfunction
Melanocortins are tiny protein molecules formed by the post-translational cleavage of proopiomelanocortin. These are bioactive peptides that are responsible for human and lower animal pigmentation patterns, energy homeostasis, and sexual function modulation. These peptides regulate numerous physiological functions by being generated in the central nervous system and peripheral tissues. Melanocortins elicit their varied biological effects by binding to a separate family of G protein, two primary proteolytic enzymes, proconvertases 1 and 2, according to the recent research. These breakthroughs have opened up new avenues for research into the role of melanocortins, antagonists, and receptors in a number of physiological activities.
- 1 February 2023
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 18 (1) , 31-38
Impact of Educational Intervention on the Knowledge, Attitude, and Practice of Pharmacovigilance Among Nurses at a Tertiary Care Public Hospital
Background: Nursing students and employees remain the first point of contact in case a patient develops an adverse drug reaction in hospital settings. Thus, it is important for nurses to understand the importance of pharmacovigilance activity and implement the same in their practice. They can also contribute to drug safety by reducing medication errors and adverse drug reaction reporting. Methods: After ethics approval, an observational questionnaire-based study was conducted in 2017 that involved nursing students and nursing employees [N=390] to assess their baseline knowledge, attitude and practice towards Pharmacovigilance. Participants who consented were enrolled and a pre-training survey was conducted. Pharmacovigilance sensitization/ training sessions were conducted in the same year after getting their baseline data. Three years later in 2021, the same questionnaire was distributed to a subset of nursing students and employees [N=299] to analyze any change in their knowledge, attitude and practice towards the Pharmacovigilance activity as a posttest. Pre and post sensitization session questionnaire-based survey data was analyzed to confirm the long-term impact of conducting such pharmacovigilance awareness training. Results: The nurses’ overall performance before and after training in each of the domains of knowledge, attitude and practice were 17.53%, 72.86%, 39.69% respectively in pretest group and post test scores were 30.77%, OR-3.04, p=0.0 [Knowledge], 85.92%, OR-0.14, p=0.0 [Attitude] and 37.21%, OR-0.08, p=0.08 [Practice] in the corresponding domain. Overall, there was declining trend in the practice domain of the nurses response between the pre-test and post intervention groups however this decline was not statistically significant [p=0.08]. Conclusion: Pharmacovigilance awareness training and sensitization programs had an impact on the knowledge and attitude of nurses but there is a need to ensure that it is implemented in clinical practice.
- 1 February 2023
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 18 (1) , 31-38
Impact of Educational Intervention on the Knowledge, Attitude, and Practice of Pharmacovigilance Among Nurses at a Tertiary Care Public Hospital
Background: Nursing students and employees remain the first point of contact in case a patient develops an adverse drug reaction in hospital settings. Thus, it is important for nurses to understand the importance of pharmacovigilance activity and implement the same in their practice. They can also contribute to drug safety by reducing medication errors and adverse drug reaction reporting. Methods: After ethics approval, an observational questionnaire-based study was conducted in 2017 that involved nursing students and nursing employees [N=390] to assess their baseline knowledge, attitude and practice towards Pharmacovigilance. Participants who consented were enrolled and a pre-training survey was conducted. Pharmacovigilance sensitization/ training sessions were conducted in the same year after getting their baseline data. Three years later in 2021, the same questionnaire was distributed to a subset of nursing students and employees [N=299] to analyze any change in their knowledge, attitude and practice towards the Pharmacovigilance activity as a posttest. Pre and post sensitization session questionnaire-based survey data was analyzed to confirm the long-term impact of conducting such pharmacovigilance awareness training. Results: The nurses’ overall performance before and after training in each of the domains of knowledge, attitude and practice were 17.53%, 72.86%, 39.69% respectively in pretest group and post test scores were 30.77%, OR-3.04, p=0.0 [Knowledge], 85.92%, OR-0.14, p=0.0 [Attitude] and 37.21%, OR-0.08, p=0.08 [Practice] in the corresponding domain. Overall, there was declining trend in the practice domain of the nurses response between the pre-test and post intervention groups however this decline was not statistically significant [p=0.08]. Conclusion: Pharmacovigilance awareness training and sensitization programs had an impact on the knowledge and attitude of nurses but there is a need to ensure that it is implemented in clinical practice.
- Open Access
- 21 December 2022
- Published by Xia & He Publishing in Journal of Exploratory Research in Pharmacology
- Vol. 000 (000) , 000
Emerging Pharmacological Targets for Treatment of Dry Age-related Macular Degeneration and Geographical Atrophy
Age-related macular degeneration (AMD) is difficult to treat and causes visual impairment worldwide, especially for dry AMD. The aging phenomenon can affect macular function, manifesting as blurred central vision. There are two types of AMD: dry and wet. By 2040, some variants of AMD are estimated to affect 288 million people globally. Although wet (exudative) AMD accounts for 10% of all AMD cases, it also contributes to 90% of the cases of patients with vision loss. Therapeutic options for wet age-related macular degeneration have expanded during the last few years. The therapeutic strategies mainly rely on anti-vascular endothelial growth factor (anti-VEGF) drugs and photodynamic therapy (PDT), though the treatment approaches for dry AMD are limited to dietary supplementation to delay progression. Moreover, clinical trials with potential candidate molecules for wet AMD exceed those for dry AMD. Although the disease is not rare, there are few therapeutic targets in the pipeline for dry AMD, and these targets may serve as promising pharmacotherapeutic options in the future. The current review sheds light on successes and failures of the existing novel drug molecules and potential targets for treating dry AMD in clinical trials registered at the Clinical Trials.gov registry run by the United States Food and Drug Administration (U.S. FDA) and published in relevant journals.
- 21 December 2022
- Published by Xia & He Publishing in Journal of Exploratory Research in Pharmacology
- Vol. 000 (000) , 000
Open AccessEmerging Pharmacological Targets for Treatment of Dry Age-related Macular Degeneration and Geographical Atrophy
Age-related macular degeneration (AMD) is difficult to treat and causes visual impairment worldwide, especially for dry AMD. The aging phenomenon can affect macular function, manifesting as blurred central vision. There are two types of AMD: dry and wet. By 2040, some variants of AMD are estimated to affect 288 million people globally. Although wet (exudative) AMD accounts for 10% of all AMD cases, it also contributes to 90% of the cases of patients with vision loss. Therapeutic options for wet age-related macular degeneration have expanded during the last few years. The therapeutic strategies mainly rely on anti-vascular endothelial growth factor (anti-VEGF) drugs and photodynamic therapy (PDT), though the treatment approaches for dry AMD are limited to dietary supplementation to delay progression. Moreover, clinical trials with potential candidate molecules for wet AMD exceed those for dry AMD. Although the disease is not rare, there are few therapeutic targets in the pipeline for dry AMD, and these targets may serve as promising pharmacotherapeutic options in the future. The current review sheds light on successes and failures of the existing novel drug molecules and potential targets for treating dry AMD in clinical trials registered at the Clinical Trials.gov registry run by the United States Food and Drug Administration (U.S. FDA) and published in relevant journals.
- Open Access
- 20 December 2022
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 15 (4) , 1937-1945
Public Awareness and Perception about Drug Safety in the Population Residing in Western India - A Questionnaire Based Cross Sectional Survey.
Drug safety is an important health concern for every individual on medications. Pharmacovigilance programme focuses on the reporting, evaluation and prevention of any adverse drug reactions and needs the equal support from every stakeholder that includes health care professionals, pharmacists and public patients as well. Public participation for reporting Adverse Drug Reactions [ADR] is quite low in developing country, India. Therefore, this study was planned with objective to evaluate awareness and perception about drug safety practice and adverse drug reactions reporting system among the lay population. A validated and ethics committee approved questionnaire was distributed to consenting participants residing in the Mumbai region by reaching to the lay public through the community centers and the responses were collected from year 2019 to 2021 to assess awareness and understanding about drug safety and adverse drug reaction reporting among lay public. A total of 1876 questionnaires were collected with a response rate of 75%. 86.7% of the participants believed drugs can have both benefit and adverse effects. 62.41% participants were unaware of any common drug related side effects. Only 8.04% of the public were aware of adverse drug reactions and reporting same to adverse event Monitoring Centre and 98.3% participants never heard of adverse event monitoring center. 66.57% participants learnt about the Pharmacovigilance program through our survey. Also, it was the patient asking the doctor about potential drug related side effects [37.58%] rather than the other way round [24%]. Although the educational survey created awareness among all participants, a greater impact was seen among the younger generation [18-30 years’ age group] irrespective of their literacy status [p<0.001]. We concluded that the Pharmacovigilance program of any nation needs health care professionals to sensitize the lay public to participate in ADR reporting thereby promote patient safety.
- 20 December 2022
- Published by Oriental Scientific Publishing Company in Biomedical and Pharmacology Journal
- Vol. 15 (4) , 1937-1945
Open AccessPublic Awareness and Perception about Drug Safety in the Population Residing in Western India - A Questionnaire Based Cross Sectional Survey.
Drug safety is an important health concern for every individual on medications. Pharmacovigilance programme focuses on the reporting, evaluation and prevention of any adverse drug reactions and needs the equal support from every stakeholder that includes health care professionals, pharmacists and public patients as well. Public participation for reporting Adverse Drug Reactions [ADR] is quite low in developing country, India. Therefore, this study was planned with objective to evaluate awareness and perception about drug safety practice and adverse drug reactions reporting system among the lay population. A validated and ethics committee approved questionnaire was distributed to consenting participants residing in the Mumbai region by reaching to the lay public through the community centers and the responses were collected from year 2019 to 2021 to assess awareness and understanding about drug safety and adverse drug reaction reporting among lay public. A total of 1876 questionnaires were collected with a response rate of 75%. 86.7% of the participants believed drugs can have both benefit and adverse effects. 62.41% participants were unaware of any common drug related side effects. Only 8.04% of the public were aware of adverse drug reactions and reporting same to adverse event Monitoring Centre and 98.3% participants never heard of adverse event monitoring center. 66.57% participants learnt about the Pharmacovigilance program through our survey. Also, it was the patient asking the doctor about potential drug related side effects [37.58%] rather than the other way round [24%]. Although the educational survey created awareness among all participants, a greater impact was seen among the younger generation [18-30 years’ age group] irrespective of their literacy status [p<0.001]. We concluded that the Pharmacovigilance program of any nation needs health care professionals to sensitize the lay public to participate in ADR reporting thereby promote patient safety.
- Open Access
- 13 September 2022
- Published by Elsevier in Vaccine: X
- Vol. 12, 100216
Lot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼T vaccine and non-inferiority to separate DTwP-HB-PRP∼T and IPV antigen-matching vaccines at 6–8, 10–12, and 14–16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled study
- 13 September 2022
- Published by Elsevier in Vaccine: X
- Vol. 12, 100216
Open AccessLot-to-lot consistency of a hexavalent DTwP-IPV-HB-PRP∼T vaccine and non-inferiority to separate DTwP-HB-PRP∼T and IPV antigen-matching vaccines at 6–8, 10–12, and 14–16 weeks of age co-administered with oral rotavirus vaccine in healthy infants in India: A multi-center, randomized, controlled study
- Open Access
- 19 July 2022
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2022 (1) , 1201977
Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta‐Analysis
Background. Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction. Objectives. Objectives are to evaluate the efficacy and safety of liraglutide 3.0 mg in patients with overweight and obesity irrespective of diabetic status. Methods. We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m2) and obese (≥30 kg/m2) patients above 18 years of age. Results. We compared the pooled estimate of the study results between liraglutide 3.0 mg groups and placebo groups both in diabetic and nondiabetic patients. The efficacy outcomes that were found to be significant among respective studies involving nondiabetic patients vs. diabetic patients were mean change in body weight from baseline: 12 studies [MD = −5.04 kg (95% CI = −5.60, −4.49), P < 0.001, I2 = 92.95%] vs. 2 studies [MD = −4.14 kg (95% CI = −4.95, −3.32), P < 0.001, I2 = 0%], reduction in waist circumference from baseline: 8 studies [MD = −3.64 cm (95% CI = −4.43, −2.85), P < 0.001, I2 = 96.5%] vs. 2 studies [MD = −3.11 cm (95% CI = −3.88, −2.34), P < 0.001, I2 = 0%], BMI reduction from baseline: 5 studies [MD = −1.95 kg/m2 (95% CI = −2.22, −1.68) vs. 1 study [MD = −1.86 kg/m2 (95% CI = −2.14, −1.57), P < 0.001, I2 = 0%, P < 0.001, I2 = 95.6%], proportion of patients losing more than 5% of weight loss from baseline: 8 studies [RR = 2.21, (95% CI = 1.89, 2.58), P = 0.03, I2 = 59.02%] vs. 2 studies [RR = 2.34, (95% CI = 1.93, 2.85), P = 0.39, I2 = 0.00%], and 10% weight loss from baseline: 7 studies [RR = 3.36, (95% CI = 1.92, 5.91), P = 0.00, I2 = 87.03%] vs. 2 studies [RR = 3.64, (95% CI = 2.46, 5.40), P = 0.81, I2 = 0.00%]. Safety outcome assessment with use of liraglutide 3.0 mg compared with placebo in respective nondiabetic vs. diabetic patients revealed significant proportion of patients experiencing the adverse events: 9 studies [RR = 1.11, (95% CI = 1.04, 1.18), P = 0.00 I2 = 79.15%] vs. 2 studies [RR = 1.06, (95% CI = 1.01, 1.11), P = 0.42, I2 = 0.03%] but similar risk of serious adverse events: 9 studies [RR = 1.03, (95% CI = 0.70, 1.51), P = 0.26, I2 = 18.54%] vs. 2 studies [RR = 1.11, (95% CI = 0.67, 1.84), P = 0.25, I2 = 23.77%] and TDAEs: 4 studies [RR = 0.89, (95% CI = 0.35, 2.28), P = 0.03, I2 = 61.89%] vs. 1 study [RR = 2.53, (95% CI = 1.00, 6.37)]. However, the pooled estimates irrespective of the glycaemic status were mean change in body weight from baseline: 14 RCT [MD = −4.91 kg (95% CI = −5.43, −4.39), P < 0.001, I2 = 92.35%], reduction in waist circumference from baseline: 10 studies [MD = −3.55 cm, (95% CI = −4.21, −2.89), P < 0.001, I2 = 94.99%], BMI reduction from baseline: 6 studies [MD = −1.86 kg/m2, (95% CI = −2.14, −1.57), P < 0.001, I2 = 96.14%], and proportion of patients losing more than 5% and 10% of weight from baseline: [RR = 2.23, (95% CI = 1.98, 2.52), P < 0.001, I2 = 48.87%] and [RR = 3.28, (95% CI = 2.23, 4.83), P < 0.001, I2 = 78.98%], respectively. Also, the proportion of patients experiencing the adverse event was more with liraglutide 3.0 mg compared with placebo 11 study [RR = 1.09, (95% CI = 1.04, 1.15), P < 0.01, I2 = 76.60%] and similar risk for both serious adverse events: 11 studies [RR = 1.09, (95% CI = 1.04, 1.15), P < 0.01, I2 = 76.60%] and TDAEs: 5 studies [RR = 1.14, (95% CI = 0.50, 2.60), P < 0.01, I2 = 64.93%] with liraglutide compared with placebo. Conclusions. Liraglutide in 3.0 mg subcutaneous dose demonstrated significant weight reduction with a reasonable safety profile for patients with overweight or obesity regardless of diabetic status compared to placebo.
- 19 July 2022
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2022 (1) , 1201977
Open AccessEfficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta‐Analysis
Background. Liraglutide in a 3.0 mg subcutaneous dose daily is approved for weight reduction. Objectives. Objectives are to evaluate the efficacy and safety of liraglutide 3.0 mg in patients with overweight and obesity irrespective of diabetic status. Methods. We conducted an electronic database search in PubMed, Embase, and https://ClinicalTrial.gov to identify all randomized control trials (RCTs) that evaluated the efficacy and safety of liraglutide 3.0 mg dose compared to placebo in overweight (≥27 kg/m2) and obese (≥30 kg/m2) patients above 18 years of age. Results. We compared the pooled estimate of the study results between liraglutide 3.0 mg groups and placebo groups both in diabetic and nondiabetic patients. The efficacy outcomes that were found to be significant among respective studies involving nondiabetic patients vs. diabetic patients were mean change in body weight from baseline: 12 studies [MD = −5.04 kg (95% CI = −5.60, −4.49), P < 0.001, I2 = 92.95%] vs. 2 studies [MD = −4.14 kg (95% CI = −4.95, −3.32), P < 0.001, I2 = 0%], reduction in waist circumference from baseline: 8 studies [MD = −3.64 cm (95% CI = −4.43, −2.85), P < 0.001, I2 = 96.5%] vs. 2 studies [MD = −3.11 cm (95% CI = −3.88, −2.34), P < 0.001, I2 = 0%], BMI reduction from baseline: 5 studies [MD = −1.95 kg/m2 (95% CI = −2.22, −1.68) vs. 1 study [MD = −1.86 kg/m2 (95% CI = −2.14, −1.57), P < 0.001, I2 = 0%, P < 0.001, I2 = 95.6%], proportion of patients losing more than 5% of weight loss from baseline: 8 studies [RR = 2.21, (95% CI = 1.89, 2.58), P = 0.03, I2 = 59.02%] vs. 2 studies [RR = 2.34, (95% CI = 1.93, 2.85), P = 0.39, I2 = 0.00%], and 10% weight loss from baseline: 7 studies [RR = 3.36, (95% CI = 1.92, 5.91), P = 0.00, I2 = 87.03%] vs. 2 studies [RR = 3.64, (95% CI = 2.46, 5.40), P = 0.81, I2 = 0.00%]. Safety outcome assessment with use of liraglutide 3.0 mg compared with placebo in respective nondiabetic vs. diabetic patients revealed significant proportion of patients experiencing the adverse events: 9 studies [RR = 1.11, (95% CI = 1.04, 1.18), P = 0.00 I2 = 79.15%] vs. 2 studies [RR = 1.06, (95% CI = 1.01, 1.11), P = 0.42, I2 = 0.03%] but similar risk of serious adverse events: 9 studies [RR = 1.03, (95% CI = 0.70, 1.51), P = 0.26, I2 = 18.54%] vs. 2 studies [RR = 1.11, (95% CI = 0.67, 1.84), P = 0.25, I2 = 23.77%] and TDAEs: 4 studies [RR = 0.89, (95% CI = 0.35, 2.28), P = 0.03, I2 = 61.89%] vs. 1 study [RR = 2.53, (95% CI = 1.00, 6.37)]. However, the pooled estimates irrespective of the glycaemic status were mean change in body weight from baseline: 14 RCT [MD = −4.91 kg (95% CI = −5.43, −4.39), P < 0.001, I2 = 92.35%], reduction in waist circumference from baseline: 10 studies [MD = −3.55 cm, (95% CI = −4.21, −2.89), P < 0.001, I2 = 94.99%], BMI reduction from baseline: 6 studies [MD = −1.86 kg/m2, (95% CI = −2.14, −1.57), P < 0.001, I2 = 96.14%], and proportion of patients losing more than 5% and 10% of weight from baseline: [RR = 2.23, (95% CI = 1.98, 2.52), P < 0.001, I2 = 48.87%] and [RR = 3.28, (95% CI = 2.23, 4.83), P < 0.001, I2 = 78.98%], respectively. Also, the proportion of patients experiencing the adverse event was more with liraglutide 3.0 mg compared with placebo 11 study [RR = 1.09, (95% CI = 1.04, 1.15), P < 0.01, I2 = 76.60%] and similar risk for both serious adverse events: 11 studies [RR = 1.09, (95% CI = 1.04, 1.15), P < 0.01, I2 = 76.60%] and TDAEs: 5 studies [RR = 1.14, (95% CI = 0.50, 2.60), P < 0.01, I2 = 64.93%] with liraglutide compared with placebo. Conclusions. Liraglutide in 3.0 mg subcutaneous dose demonstrated significant weight reduction with a reasonable safety profile for patients with overweight or obesity regardless of diabetic status compared to placebo.